Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Orphan Designations For Cancer Drugs: US FDA Urged To Distinguish Tissue-Agnostic From Tumor-Specific Diseases

May 11 2018

• By Sue Sutter

Related Content

Indication 'Carve In' Allowed Under Generic Labeling 'Carve-Out' Authority, US FDA Says

Nov 29 2017

Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes

Oct 17 2017

Spark's Early Christmas Present: US FDA Approves Luxturna For Vision Loss

Dec 19 2017

Biomarker-Led Claim Is Small Step For Merck's Keytruda, Giant Leap For Cancer Indications

May 23 2017

US FDA's Acting Orphan Products Development Director Has Gene Therapy Background

May 06 2018

Spring Awakening: NDA Submissions To Watch For

Mar 12 2018

Related Companies

Merck & Co., Inc.

Ignyta, Inc.

Loxo Oncology at Lilly

Bayer AG

Takeda Pharmaceutical Co. Ltd.

Spark Therapeutics, Inc.

Additional Topics

United States Rare Diseases Review Pathway FDA Policy Cancer BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window